

6. (Twice Amended) An isolated polynucleotide comprising at least the open reading frame of a sequence recited in SEQ ID NO:474.

Please add new claims 85-89 to read as follows:

85. (New) An isolated polynucleotide useful in the detection of breast cancer comprising a sequence complementary to the sequence provided in SEQ ID NO:474.

86. (New) An isolated polynucleotide useful in the detection of breast cancer comprising a sequence consisting of at least 20 contiguous nucleotides of a sequence provided in SEQ ID NO:474.

87. (New) An isolated polynucleotide useful in the detection of breast cancer comprising a sequence that hybridizes to a sequence provided in SEQ ID NO:474, under moderately stringent conditions.

88. (New) An isolated polynucleotide useful in the detection of breast cancer comprising a sequence having at least 90% identity to a sequence of SEQ ID NO:474.

89. (New) An isolated polynucleotide useful in the detection of breast cancer comprising a degenerate variant of a sequence provided in SEQ ID NO:474.

REMARKS

Applicants kindly thank the Examiner for the productive interview conducted at the USPTO on July 18, 2002. Favorable reconsideration of the subject application is respectfully requested in view of the following remarks. With the above amendment, claim 6 has been amended. Claim 80 has been canceled and rewritten as independent claims 85-89. Thus, with this amendment, claims 6 and 81-89 are pending. It is urged that support for the amendments may be found throughout the specification as